I am a board-certified medical oncologist who specializes in caring for patients with lung cancer. I am part of a team of physicians from multiple disciplines — including thoracic surgery, radiation oncology, pathology and interventional radiology — who meet weekly and collaborate to determine the optimal treatment plan for our patients. As part of our suite of treatment options, my colleagues and I run and participate in a multitude of clinical trials, all of which are available to patients who qualify and wish to participate. These trials range from therapeutic trials evaluating new treatment approaches to translational trials that help us learn more about lung cancer.
In the clinic, my team and I focus on personalizing our care for each patient not only to his or her type of cancer and its genetics but to the patient’s personal circumstances, beliefs, and wishes. We consider a patient’s disease characteristics and biological characteristics in light of the priorities of each patient and his or her family, and discuss treatment options — including clinical trial opportunities when appropriate — to provide the best care for our patients as we work with them to fight their cancer.
While I care for patients with all types and stages of lung cancer, my research focuses on the use of multimodality therapies (such as chemotherapy plus radiation or surgery) to improve cure rates in patients with early-stage non-small cell lung cancer.
At Memorial Sloan Kettering, I am the lead investigator on all trials evaluating multimodality treatment for non-small cell lung cancers. These trials focus on developing new treatment regimens by finding different applications for standard drugs or testing new therapeutic agents with surgery and/or radiation. Additionally, I conduct research to identify biomarkers that are unique to a patient or his or her cancer. These biomarkers can be used to preferentially select a drug treatment regimen that is likely to be more effective against that individual’s lung cancer. Discovering such biomarkers will allow us to optimize the use of available chemotherapies to maximize the benefit of anticancer treatments while minimizing the patient’s exposure to side effects of less-active treatments. This is a promising and active research niche in the area of personalized medicine where we aim to improve the outcomes and quality of life of patients diagnosed with lung cancer.
- Clinical Expertise: Non-Small Cell Lung Cancer; Early-Stage Non-Small Cell Lung Cancer; Multilmodality Therapies
- Languages Spoken: English
- Education: MD, New York University
- Residencies: Internal Medicine - New York Presbyterian/Weill Cornell Medical Center
- Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Jamie E. Chaft
- A Phase II Study of Preoperative Nivolumab Immunotherapy to Treat Operable Non-Small Cell Lung Cancer
- A Phase III Study of Crizotinib Given After Surgery for Early-Stage ALK-Positive Non-Small Cell Lung Cancer
- A Phase III Study of Erlotinib Given After Surgery for Early-Stage EGFR-Positive Non-Small Cell Lung Cancer
- A Phase III Study of Immunotherapy with Nivolumab, Nivolumab/Ipilimumab, or Placebo as Maintenance Therapy in Patients with Extensive-Stage Disease Small Cell Lung Cancer
- A Phase III Study of Nivolumab Immunotherapy versus Observation After Surgery for Non-Small Cell Lung Cancer
Clinical Trials Co-Investigated by Jamie E. Chaft
- A Phase I Study of Stereotactic Body Radiation Therapy for Inoperable Locally Advanced Non-Small Cell Lung Cancer
- A Phase II Study of Nivolumab Immunotherapy Alone and with Other Anticancer Drugs for Advanced Non-Small Cell Lung Cancer
- A Phase III Study Comparing Standard Chemotherapy, Nivolumab Alone, or Nivolumab plus Ipilimumab Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer
- A Phase III Study of Chemotherapy with Either Proton Therapy or Conventional Photon Radiation Therapy to Treat Inoperable Stage II-IIIB Non-Small Cell Lung Cancer
- A Study Assessing the Predictive Value of Tumor Hypoxia (Low Oxygen Supply) in Patients with Non-Small Cell Lung Cancer
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- Lung Cancer Exercise Training Study (LUNGEVITY): A Study of Aerobic Training, Resistance Training, or Both in Lung Cancer Patients After Surgery
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more